Relative Bioavailability Study of HR19042 in Healthy Subjects
Status:
COMPLETED
Trial end date:
2024-01-25
Target enrollment:
Participant gender:
Summary
This is a single-center, randomized, open-label, three-period, dual Latin square crossover study.
Primary Objective
1. To evaluate the oral relative bioavailability of HR19042 Capsules compared with budesonide delayed-release capsules (Tarpeyo) and budesonide enteric-coated capsules (Budenofalk).
Secondary Objective
2. To assess safety following administration.